Search Results - "Karlsson, Conny"

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS by Silvennoinen, Raija, Partanen, Anu, Waage, Anders, Pečeliūnas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Uttervall, Katarina, Säily, Marjaana, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Axelsson, Per, Svensson, Ronald, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Klimkowska, Monika, Matuzeviciene, Reda, Hoyseter Fenstad, Mona, Ilveskero, Sorella, Nahi, Hareth

Get full text

Impact of 1q gains on treatment outcomes of patients with newly diagnosed multiple myeloma in a real‐world Swedish population receiving modern treatment by Lemonakis, Konstantinos, Olsson‐Arvidsson, Linda, Karlsson, Conny, Johansson, Bertil, Hansson, Markus

“…Background Amplification of 1q (amp(1q); ≥4 1q copies) has repeatedly been reported to predict a worse outcome in multiple myeloma (MM), whereas the impact of…”
Get full text

P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients by Silvennoinen, Raija, Waage, Anders, Peceliunas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Uttervall, Katarina, Säily, Marjaana, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Partanen, Anu, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Svensson, Ronald, Axelsson, Per, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Nahi, Hareth

Get full text

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients by Silvennoinen, Raija Helena, Waage, Anders, Peceliunas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Säily, Marjaana, Putkonen, Mervi, Carlson, Kristina, Haukaas, Einar, Sankelo, Marja, Partanen, Anu, Szatkowski, Damian L., Hansson, Markus, Marttila, Anu, Ahlberg, Lucia, Axelsson, Per, Lauri, Birgitta, Mikkola, Maija Helena, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Klimkowska, Monika, Matuzeviciene, Reda, Hoysaeter Fenstad, Mona, Ilveskero, Sorella, Nahi, Hareth

“…Introduction Autologous stem cell transplantation (ASCT) combined with novel agents is considered as the standard treatment for eligible patients < 70(-75)…”
Get full text

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group by Partanen, Anu, Waage, Anders, Peceliunas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Säily, Marjaana, Uttervall, Katarina, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Svensson, Ronald, Axelsson, Per, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Klimkowska, Monika, Matuzeviciene, Reda, Fenstad, Mona Hoysaeter, Ilveskero, Sorella, Pelliniemi, Tarja-Terttu, Nahi, Hareth, Silvennoinen, Raija

“…Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study…”
Get full text

Blood-ocular and blood-brain barrier function in streptozocin-induced diabetes in rats by Mäepea, O, Karlsson, C, Alm, A

“…Edetic acid labeled with chromium 51 was injected intravenously in normal rats and in rats with streptozocin-induced diabetes. One hour after the injection the…”
Get more information